TP53 and central nervous system cancer: The U87-MG (homozygous PTEN c.209+1G > T, and TERT c.228C > T, -124C > T mutations) and A172 (ABL1–CBFB gene fusion) human glioma cell lines carrying wild type TP53 also reacted with massive apoptosis to mEHT treatment through DNA damage and poly-adenyl ribose polymerase (PARP) downregulation-induced E2F1 stabilization and upregulation [37].